Hoth Therapeutics declares interim data for pruritus treatment from Phase IIa trial of HT-001

Hoth Therapeutics, a biopharmaceutical company based in New York, has shared interim results from its ongoing Phase IIa CLEER-001 trial of HT-001, a topical non-steroidal therapy aimed at treating pruritus caused by epidermal growth factor receptor (EGFR) inhibitors. The investigational treatment, intended for localized relief from itching and irritation without systemic side effects, showed promising results over 21 days. Participants experienced a 50% reduction in pruritus severity, with average scores improving from 1.6 at baseline to 0.8 by day 21. Noticeable symptom relief began as early as day seven, with some individuals reporting complete resolution within the study period. HT-001 was found to be safe and well-tolerated, with no serious adverse events linked to treatment. The randomized, double-blind trial continues to enroll both cohorts. These findings reinforce HT-001’s potential to significantly improve quality of life for cancer patients dealing with EGFR inhibitor-related skin conditions, supporting continued development of the therapy.

22-04-2025